KLRK1 and acute myeloid leukemia: CD33 and CD123 are the most used targets, but recently CAR-NK cells directed against NKG2D, CD70, CD38, and CLL1 have been generated and proved cytotoxic activity in AML preclinical studies [138,139,140,141].